EyeGate Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EyeGate Pharmaceuticals, Inc.
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
A number of pivotal studies are expected to report top-line data in the third quarter. Here, with the help of Informa Pharma's Biomedtracker, we take a look at eight of those likely to be major catalysts for their sponsors.
Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- EyeGate Pharma S.A.S.
- Jade Therapeutics, Inc.
- Optis France S.A.
- Panoptes Pharma GmbH